Understanding the biology of Pulmonary Recurrent Respiratory Papillomatosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and analyze tissue samples from patients diagnosed with Pulmonary Recurrent Respiratory Papillomatosis (pRRP), a rare disease caused by HPV types 6 and 11. By establishing a tissue repository, the study will facilitate genetic and immunologic research to uncover the underlying biology of this condition and the immune responses involved. The collected samples will include both fresh and archived tissues, which will be de-identified to protect patient privacy. The goal is to develop novel therapies based on the findings from these analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* History of HPV-associated Recurrent Respiratory Papillomatosis
* Has pulmonary lesions

Exclusion Criteria:

* None

Where it's running

• Yale School of Medicine
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Sara Pai — Yale University
• Study coordinator: Sara Pai, MD, PhD
• Email: RRPBiorepository@yale.edu
• Phone: 203-785-5820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enhanced COPD care for people being checked for lung cancer

  This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.

  Recruiting Region of Southern Denmark · Vejle · NCT07543601

• Autologous dendritic cell vaccine for recurrent respiratory papillomatosis

  This test tries a vaccine made from your own dendritic cells loaded with HPV6 peptides to see if it is safe and stimulates the immune system in people with HPV6-positive recurrent respiratory papillomatosis.

  Recruiting Phase 1 Mayo Clinic · Scottsdale, Arizona · NCT07317154

• Rarecells blood test combining circulating tumor cell DNA and circulating tumor DNA for early lung cancer detection

  This test checks whether combining Rarecells ISET® circulating tumor cell DNA and circulating tumor DNA from a blood sample can find early or returning lung cancer in people with operable tumors.

  Recruiting Rarecells Diagnostics SAS · Roma · NCT06546007

• Treatment of Recurrent Respiratory Papillomatosis with PRGN-2012

  This study is testing a new treatment called PRGN-2012 in adults with recurrent respiratory papillomatosis to see if it helps reduce their symptoms after multiple surgeries.

  Recruiting at 3 sites Phase 4 Precigen, Inc · Atlanta, Georgia and 2 other locations · NCT06538480

• Innovative care program for lung cancer survivors

  This study is testing a new care program designed to help lung cancer survivors in Kentucky feel better and improve their quality of life compared to standard care.

  Recruiting University of Kentucky · Lexington, Kentucky · NCT05857995

• Erector spinae block for pain management in thoracic surgery

  This study is testing if a special pain relief technique using erector spinae blocks can help patients having lung surgery feel less pain and need fewer pain medications after their operation.

  Recruiting Phase 4 George Washington University · Washington D.C., District of Columbia · NCT05521789

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.